{"entity":{"id":"hopital-abderrahmen-mami-ariana","kind":"institution","name":"Hôpital Abderrahmen Mami, Ariana","aka":["Abderrahmen Mami Hospital","Hôpital Abderrahmen Mami de l'Ariana"],"tldr":"A hospital in Ariana, north of Tunis, with a radiotherapy unit of two linear accelerators. It is a site for an international breast cancer trial.","summary":"IAEA DIRAC's equipment report, read on 11 November 2026 with the entry updated in 2026, lists the hospital's radiotherapy unit in Ariana with two linear accelerators and a CT scanner, and no brachytherapy. ClinicalTrials.gov lists Abderrahmen Mami Hospital, Aryanah, as a site of the trial of inavolisib with pertuzumab and trastuzumab in PIK3CA-mutated HER2-positive breast cancer (NCT05894239). OnCo found no website for the hospital.","asOf":"2026-11-11","links":[{"label":"IAEA DIRAC: radiotherapy centres and equipment (read 11 November 2026)","url":"https://dirac.iaea.org/Data/CountriesLight"},{"label":"ClinicalTrials.gov NCT05894239: site list","url":"https://clinicaltrials.gov/study/NCT05894239"}],"tags":[],"related":[],"cancers":["breast-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["institut-salah-azaiez"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Ariana","country":"TN","lat":36.869,"lng":10.178,"institutionType":"hospital","programs":["Radiotherapy (two linear accelerators in IAEA DIRAC)"]},"route":"/institutions/hopital-abderrahmen-mami-ariana/","neighbours":{"cancer":[{"id":"breast-cancer","kind":"cancer","name":"Breast cancer (all types)","route":"/cancers/breast-cancer/"}],"institution":[{"id":"institut-salah-azaiez","kind":"institution","name":"Institut Salah Azaïez","route":"/institutions/institut-salah-azaiez/"}],"trial":[{"id":"nct05894239","kind":"trial","name":"A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer","route":"/trials/nct05894239/"}]}}